Home Autophagy Autophagy activator - Lipoxygenase inhibitor - COX inhibitor - ERK inhibitor - JNK inhibitor - Src inhibitor - STAT inhibitor - AMPK activator - Mitophagy activator - Apoptosis related activator - Sirtuin inhibitor - IκB/IKK inhibitor Resveratrol For research use only.

Resveratrol

Synonyms: SRT501

Resveratrol has a wide spectrum of targets including cyclooxygenases(i.e. COX, IC50=1.1 μM), lipooxygenases（LOX, IC50=2.7 μM）, kinases, sirtuins and other proteins. It has anti-cancer, anti-inflammatory, blood-sugar-lowering and other beneficial cardiovascular effects. Resveratrol induces mitophagy/autophagy and autophagy-dependent apoptosis.

Resveratrol Chemical Structure

Resveratrol Chemical Structure

CAS No. 501-36-0

Purity & Quality Control

Resveratrol Related Products

Signaling Pathway

Autophagy Signaling Pathways

Autophagy Signaling Pathway

Cell Data

Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human HL60 cell line Proliferation assay Antiproliferative activity against human HL60 cell line, IC50=5 μM 16686543
human K562 cell line Proliferation assay Antiproliferative activity against human K562 cell line expressing Bcr-Abl, IC50=28 μM 16686543
HUVEC Function assay 100 μM 1 day Induction of mitochondrial biogenesis in H2O2-induced HUVEC at 100 umol/L pretreated for 1 day followed by compound washout and H2O2-treatment measured after 10 days by MitoTracker Red staining-based assay 23859249
Hepa1clc7 Cytotoxicity assay 72 hrs Cytotoxicity against mouse Hepa1clc7 cells after 72 hrs, IC50=11μM. 10075742
MCF7 Function assay 6 hrs Inhibition of phorbol ester-induced ornithine decarboxylase in human MCF7 cells after 6 hrs, IC50=19μM. 10075742
U937 Function assay Inhibition of [14C]dehydroascorbic acid uptake in human U937 cells by Michaelis-Menten plot, Ki=35μM. 11277764
U937 Function assay Inhibition of 2-[1,2-3H(N)]deoxy-D-glucose uptake in human U937 cells by scintillation spectrometry in presence of sodium-free buffer 11277764
HL60 Function assay Inhibition of 2-[1,2-3H(N)]deoxy-D-glucose uptake in human HL60 cells by scintillation spectrometry in presence of sodium-free buffer 11277764
U937 Function assay Inhibition of [14C]dehydroascorbic acid uptake in human U937 cells by scintillation spectrometry in presence of sodium-free buffer 11277764
HL60 Function assay Inhibition of [14C]dehydroascorbic acid uptake in human HL60 cells by scintillation spectrometry in presence of sodium-free buffer 11277764
CHO Function assay Blockade of rat Glut1 expressed in CHO cells assessed as inhibition of 2-[1,2-3H(N)]deoxy-D-glucose uptake by scintillation spectrometry 11277764
CHO Function assay Blockade of rat Glut1 expressed in CHO cells assessed as inhibition of [14C]dehydroascorbic acid uptake by scintillation spectrometry 11277764
CHO Function assay Blockade of human Glut3 expressed in CHO cells assessed as inhibition of 2-[1,2-3H(N)]deoxy-D-glucose uptake by scintillation spectrometry 11277764
CHO Function assay Blockade of human Glut3 expressed in CHO cells assessed as inhibition of [14C]dehydroascorbic acid uptake by scintillation spectrometry 11277764
HL60 Function assay In vitro inhibitory concentration against proliferation of HL60 cells, IC50=5μM. 12877593
RAW264.7 Function assay Inhibitory activity against nitric oxide production in lipopolysaccharide-activated mouse macrophage RAW264.7 cells, IC50=15.9μM. 14552759
RAW264.7 Function assay Inhibitory effect on PGE-2 production in LPS-stimulated RAW264.7 cells, IC50=4μM. 15080988
RAW264.7 Function assay inhibitory concentration against PGE-2 production in LPS-stimulated RAW264.7 cells, IC50=20.8μM. 15501064
T47D Function assay Estrogenic activity in human T47D cells assessed as drug level causing stimulation of cell proliferation equivalent to 10 pM estradiol by alamar blue assay, Activity=0.03μM. 15787436
MCF7 Function assay Estrogenic activity in human MCF7 cells assessed as drug level causing stimulation of cell proliferation equivalent to 10 pM estradiol by alamar blue assay, Activity=1.6μM. 15787436
MDA-MB-231 Antiproliferative assay Inhibitory concentration required for antiproliferative activity against human MDA-MB-231 cells, IC50=20.5μM. 16250636
U937 Cytotoxicity assay Cytotoxicity against human U937 cells after 48 hrs by WST1 test, IC50=17μM. 16252924
HL60 Antiproliferative assay Antiproliferative activity against human HL60 cells, IC50=5μM. 16580204
HEK293T Function assay Inhibition of TNF-alpha-induced NF-kappaB activation in HEK293T cells, IC50=20μM. 17125270
BV2 Function assay Suppression of LPS-stimulated COX2 mRNA expression in mouse BV2 cells at 20 uM 17125270
RAW 264.7 Function assay Inhibition of LPS and TNF-alpha-activated NO production in murine RAW 264.7 cells, IC50=23.5μM. 17253844
Hepa 1c1c7c1 Function assay 12.5 uM 24 hrs Induction of quinone reductase in mouse mutant Hepa 1c1c7c1 cells at 12.5 uM after 24 hrs relative to control, Activity=1.16μM. 17316918
Hepa 1c1c7 Function assay 12.5 uM 24 hrs Induction of quinone reductase activity in mouse Hepa 1c1c7 cells at 12.5 uM after 24 hrs relative to control, Activity=1.24μM. 17316918
MC3T3-E1 Function assay 1 uM Reversal of increase in ER.DNA complex in mouse MC3T3-E1 cells transfected with dominant-negative mutant Src expression vector at 1 uM by RT-PCR 17513867
MDA-MB-231 Function assay Reversal of induction of FOXO3a activity in human MDA-MB-231 cells transfected with FOXO3a-specific small interfering RNA 17513867
MDA-MB-231 Function assay Induction of FOXO3a activity in human MDA-MB-231 cells 17513867
MC3T3-E1 Function assay 1 uM Reversal of increase in Src kinase phosphorylation in mouse MC3T3-E1 cells at 1 uM in presence of PP2 17513867
MC3T3-E1 Function assay 1 uM Reversal of increase in Src kinase phosphorylation in mouse MC3T3-E1 cells transfected with dominant-negative mutant Src expression vector at 1 uM 17513867
MC3T3-E1 Function assay 1 uM Increase in Src kinase phosphorylation in mouse MC3T3-E1 cells at 1 uM 17513867
MC3T3-E1 Function assay Reversal of increase in DNA-binding activity of ERalpha in nuclear extracts of mouse MC3T3-E1 cells by electrophoretic mobility shift assays in presence of short interfering ER alpha-RNA 17513867
MC3T3-E1 Function assay Reversal of increase in DNA-binding activity of ERalpha in nuclear extracts of mouse MC3T3-E1 cells by electrophoretic mobility shift assays in presence of ICI-182780 17513867
T47D Antiproliferative assay 1 uM Antiproliferative activity against human T47D cells at 1 uM by flow cytometry 17513867
primary osteoblast cells Function assay 1 uM Reversal of increase in ER.DNA complex in rat primary osteoblast cells transfected with dominant-negative mutant Src expression vector at 1 uM by RT-PCR 17513867
MC3T3-E1 Function assay 1 uM Reversal of increase in pBMP2 expression in mouse MC3T3-E1 cells at 1 uM by luciferase method in presence of PP2 17513867
MC3T3-E1 Function assay 1 uM Induction of ER association with BMP2 promoter in mouse MC3T3-E1 cells at 1 uM by ChiP assay 17513867
MC3T3-E1 Function assay 1 uM Reversal of induction in nuclear translocation of ERalpha in mouse MC3T3-E1 cells transfected with dominant-negative mutant Src expression vector at 1 uM 17513867
MG63 Function assay 0.1 to 10 uM 24 hr Increase in proliferation of human MG63 cells at 0.1 to 10 uM after 24 hr by flow cytometry 17513867
MC3T3-E1 Function assay Increase in DNA-binding activity of ERalpha in nuclear extracts of mouse MC3T3-E1 cells by electrophoretic mobility shift assays 17513867
MCF7 Antiproliferative assay 1 uM Antiproliferative activity against human MCF7 cells at 1 uM by flow cytometry 17513867
MC3T3-E1 Function assay 1 uM Reversal of increase in pBMP2 expression in mouse MC3T3-E1 cells transfected with dominant-negative mutant Src expression vector at 1 uM by luciferase method 17513867
MC3T3-E1 Function assay 0.1 to 10 uM 7 days Increase in ALP activity in mouse MC3T3-E1 cells at 0.1 to 10 uM after 7 days 17513867
primary osteoblast cells Function assay 0.1 to 10 uM 7 days Increase in ALP activity in rat primary osteoblast cells at 0.1 to 10 uM after 7 days 17513867
MC3T3-E1 Function assay 1 uM 72 hrs Increase in osteocalcin mRNA levels in mouse MC3T3-E1 cells at 1 uM after 72 hrs by RT-PCR 17513867
MG63 Function assay 1 uM 72 hrs Increase in osteocalcin mRNA levels in human MG63 cells at 1 uM after 72 hrs by RT-PCR 17513867
primary osteoblast cells Function assay 1 uM 72 hrs Increase in osteocalcin mRNA levels in rat primary osteoblast cells at 1 uM after 72 hrs by RT-PCR 17513867
MC3T3-E1 Function assay 1 uM 72 hrs Increase in osteocalcin levels in mouse MC3T3-E1 cells at 1 uM after 72 hrs by ELISA 17513867
MG63 Function assay 1 uM 72 hrs Increase in osteocalcin levels in human MG63 cells at 1 uM after 72 hrs by ELISA 17513867
primary osteoblast cells Function assay 1 uM 72 hrs Increase in osteocalcin levels in rat primary osteoblast cells at 1 uM after 72 hrs by ELISA 17513867
MC3T3-E1 Function assay 1 uM 72 hrs Increase in osteopontin mRNA levels in mouse MC3T3-E1 cells at 1 uM after 72 hrs by RT-PCR 17513867
MG63 Function assay 1 uM 72 hrs Increase in osteopontin mRNA levels in human MG63 cells at 1 uM after 72 hrs by RT-PCR 17513867
primary osteoblast cells Function assay 1 uM 72 hrs Increase in osteopontin mRNA levels in rat primary osteoblast cells at 1 uM after 72 hrs by RT-PCR 17513867
MC3T3-E1 Function assay 1 uM 72 hrs Increase in osteopontin levels in mouse MC3T3-E1 cells at 1 uM after 72 hrs by ELISA 17513867
MG63 Function assay 1 uM 72 hrs Increase in osteopontin levels in human MG63 cells at 1 uM after 72 hrs by ELISA 17513867
primary osteoblast cells Function assay 1 uM 72 hrs Increase in osteopontin levels in rat primary osteoblast cells at 1 uM after 72 hrs by ELISA 17513867
MC3T3-E1 Function assay 24 hrs Inhibition of TNF-alpha-induced apoptosis in mouse MC3T3-E1 cells after 24 hrs by flow cytometry 17513867
primary osteoblast cells Function assay 24 hrs Inhibition of etoposide-induced apoptosis in rat primary osteoblast cells after 24 hrs by flow cytometry 17513867
primary osteoblast cells Function assay 24 hrs Inhibition of TNF-alpha-induced apoptosis in rat primary osteoblast cells after 24 hrs by flow cytometry 17513867
MCF7 Function assay 1 uM Reduction in anchorage-independent colony formation of human MCF7 cells at 1 uM by soft agar colony forming assay 17513867
T47D Function assay 1 uM Reduction in anchorage-independent colony formation of human T47D cells at 1 uM by soft agar colony forming assay 17513867
primary osteoblast cells Function assay 1 uM Increase in BMP2 mRNA levels in rat primary osteoblast cells at 1 uM by RT-PCR method 17513867
primary osteoblast cells Function assay 1 uM Reversal of increase in ER.DNA complex in rat primary osteoblast cells at 1 uM by RT-PCR in presence of PP2 17513867
MC3T3-E1 Function assay 1 uM 4 hrs Increase in BMP2 expression in mouse MC3T3-E1 cells expressing pBMP2 mutant at 1 uM after 4 hrs by luciferase method relative to control 17513867
MC3T3-E1 Function assay 1 uM 4 hrs Increase in BMP2 expression in mouse MC3T3-E1 cells expressing pBMP2delta1 mutant at 1 uM after 4 hrs by luciferase method relative to control 17513867
MC3T3-E1 Function assay 1 uM Reversal of induction of BMP2 expression in mouse MC3T3-E1 cells at 1 uM by Western blot in presence of ICI-182780 17513867
MC3T3-E1 Function assay 1 uM Reversal of induction of BMP2 expression in mouse MC3T3-E1 cells at 1 uM by Western blot in presence of short interfering ERalpha-RNA 17513867
MC3T3-E1 Function assay 1 uM Reversal of induction in nuclear translocation of ERalpha in mouse MC3T3-E1 cells at 1 uM in presence of PP2 17513867
MC3T3-E1 Function assay 1 uM Reversal of induction in BMP2 expression in mouse MC3T3-E1 cells transfected with dominant-negative mutant Src expression vector at 1 uM by Western blot 17513867
MC3T3-E1 Function assay 1 uM Reversal of induction in BMP2 expression in mouse MC3T3-E1 cells at 1 uM by Western blot in presence of PP2 17513867
MC3T3-E1 Function assay 1 uM Reversal of increase in ER.DNA complex in mouse MC3T3-E1 cells at 1 uM by RT-PCR in presence of PP2 17513867
primary osteoblast cells Function assay 1 uM Reversal of increase in pBMP2 expression in rat primary osteoblast cells transfected with dominant-negative mutant Src expression vector at 1 uM by luciferase method 17513867
primary osteoblast cells Function assay 1 uM Reversal of increase in pBMP2 expression in rat primary osteoblast cells at 1 uM by luciferase method in presence of PP2 17513867
MC3T3-E1 Function assay Reversal of increase in DNA-binding activity of ERalpha in nuclear extracts of mouse MC3T3-E1 cells transfected with dominant-negative mutant Src expression vector by electrophoretic mobility shift assays 17513867
MC3T3-E1 Function assay Reversal of increase in DNA-binding activity of ERalpha in nuclear extracts of mouse MC3T3-E1 cells by electrophoretic mobility shift assays in presence of PP2 17513867
MC3T3-E1 Function assay 1 uM Reversal of increase in BMP2 expression in mouse MC3T3-E1 cells expressing small interfering RNA for FOXA1 protein at 1 uM by Western blot 17513867
MC3T3-E1 Function assay 1 uM Reversal of increase in pBMP2 expression in mouse MC3T3-E1 cells expressing small interfering RNA for FOXA1 protein at 1 uM by luciferase method 17513867
MC3T3-E1 Function assay 1 uM Reversal of increase in ER.DNA complex in mouse MC3T3-E1 cells expressing small interfering RNA for FOXA1 protein at 1 uM by RT-PCR 17513867
MDA-MB-231 Function assay Reversal of inhibition in anchorage-independent colony formation of human MDA-MB-231 cells transfected with FOXO3a-specific small interfering RNA by soft agar colony forming assay 17513867
MDA-MB-231 Function assay Inhibition of IGF-induced FOXO3a phosphorylation at Thr32 residue in human MDA-MB-231 cells by Western blot 17513867
MDA-MB-231 Function assay Inhibition of IGF-induced Akt phosphorylation in human MDA-MB-231 cells by Western blot 17513867
MDA-MB-231 Function assay Reversal of induction of Akt inactivation in human MDA-MB-231 cells transfected with constitutively activated Akt mutant 17513867
MDA-MB-231 Function assay Reversal of induction of FOXO3a nuclear accumulation in human MDA-MB-231 cells transfected with constitutively activated Akt mutant 17513867
MDA-MB-231 Function assay Reversal of induction of FOXO3a activity in human MDA-MB-231 cells transfected with constitutively activated Akt mutant 17513867
MDA-MB-231 Function assay Enhancement of Akt inactivation in human MDA-MB-231 cells transfected with dominant negative Akt mutant 17513867
MDA-MB-231 Function assay Enhancement of FOXO3a nuclear accumulation in human MDA-MB-231 cells transfected with dominant negative Akt mutant 17513867
MDA-MB-231 Function assay Enhancement of FOXO3a activity in human MDA-MB-231 cells transfected with dominant negative Akt mutant 17513867
MDA-MB-231 Function assay 10 mg/kg 2 days Decrease in Akt activation in human MDA-MB-231 cells expressing FOXO3a-specific small interfering RNA xenografted in nude mice at 10 mg/kg for 2 days 17513867
MDA-MB-231 Function assay 10 mg/kg 2 days Induction of FOXO3a nuclear accumulation in human MDA-MB-231 cells FOXO3a-specific small interfering RNA xenografted in nude mice at 10 mg/kg for 2 days 17513867
MDA-MB-231 Antiproliferative assay 1 uM Antiproliferative activity against human MDA-MB-231 cells at 1 uM by flow cytometry 17513867
MDA-MB-231 Function assay 1 uM Reduction in anchorage-independent colony formation of human MDA-MB-231 cells at 1 uM by soft agar colony forming assay 17513867
MC3T3-E1 Function assay 1 uM 48 hrs Inhibition of induction of ALP activity in mouse MC3T3-E1 cells at 1 uM after 48 hrs in presence of BMP2-specific neutralizing antibody 17513867
primary osteoblast cells Function assay 1 uM 48 hrs Inhibition of induction of ALP activity in rat primary osteoblast cells at 1 uM after 48 hrs in presence of BMP2-specific neutralizing antibody 17513867
MC3T3-E1 Function assay 1 uM 48 hrs Inhibition of induction of ALP activity in mouse MC3T3-E1 cells at 1 uM after 48 hrs in presence of noggin 17513867
primary osteoblast cells Function assay 1 uM 48 hrs Inhibition of induction of ALP activity in rat primary osteoblast cells at 1 uM after 48 hrs in presence of noggin 17513867
primary osteoblast cells Antiapoptotic activity assay 1 uM 48 hrs Inhibition of antiapoptotic activity in rat primary osteoblast cells at 1 uM after 48 hrs in presence of BMP2-specific neutralizing antibody 17513867
primary osteoblast cells Antiapoptotic activity assay 1 uM 48 hrs Inhibition of antiapoptotic activity in rat primary osteoblast cells at 1 uM after 48 hrs in presence of noggin 17513867
MC3T3-E1 Function assay 0.1 to 10 uM 24 hr Increase in proliferation of mouse MC3T3-E1 cells assessed as fraction of cells in S phase at 0.1 to 10 uM after 24 hr by flow cytometry 17513867
primary osteoblast cells Function assay 0.1 to 10 uM 24 hr Increase in proliferation of rat primary osteoblast cells at 0.1 to 10 uM after 24 hr by flow cytometry 17513867
MG63 Function assay 0.1 to 10 uM 7 days Increase in ALP activity in human MG63 cells at 0.1 to 10 uM after 7 days 17513867
MC3T3-E1 Function assay 24 hrs Inhibition of etoposide-induced apoptosis in mouse MC3T3-E1 cells after 24 hrs by flow cytometry 17513867
MC3T3-E1 Antiapoptotic activity assay 1 uM 48 hrs Inhibition of antiapoptotic activity in mouse MC3T3-E1 cells at 1 uM after 48 hrs in presence of BMP2-specific neutralizing antibody 17513867
MC3T3-E1 Antiapoptotic activity assay 1 uM 48 hrs Inhibition of antiapoptotic activity in mouse MC3T3-E1 cells at 1 uM after 48 hrs in presence of noggin 17513867
RAW264.7 Function assay Inhibition of phagocytosis of FITC-conjugated Escherichia coli K12 in mouse RAW264.7 cells assessed as reduction in ratio of number of bacterial cells to phagocytes using trypan blue staining by flow cytometry 17938187
RAW264.7 Function assay Inhibition of phagocytosis of FITC-conjugated Staphylococcus aureus 209P in mouse RAW264.7 cells assessed as reduction in ratio of number of bacterial cells to phagocytes using trypan blue staining by flow cytometry 17938187
THP1 Function assay Inhibition of phagocytosis of FITC-conjugated Escherichia coli K12 in human THP1 cells assessed as reduction in ratio of number of bacterial cells to phagocytes using trypan blue staining by flow cytometry 17938187
THP1 Function assay Inhibition of phagocytosis of FITC-conjugated Staphylococcus aureus 209P in human THP1 cells assessed as reduction in ratio of number of bacterial cells to phagocytes using trypan blue staining by flow cytometry 17938187
THP1 Function assay 1 hr Inhibition of FSL-1-induced increase in phagocytosis of FITC-conjugated Escherichia coli K12 in human THP1 cells assessed as reduction in number of cells phagocytosing bacteria per cell after 1 hr by CLSM 17938187
THP1 Function assay 1 hr Inhibition of FSL-1-induced increase in phagocytosis of FITC-conjugated Escherichia coli K12 in human THP1 cells assessed as reduction in number of phagocytosing bacteria to total number of cells after 1 hr by CLSM 17938187
HEK293 Function assay 1 hr Inhibition of heat killed Escherichia coli K12-induced NF-kappaB activation in HEK293 cells expressing TLR2 pretreated for 1 hr before 6 hrs heat killed bacterial stimulation by luciferase reporter gene assay 17938187
HEK293 Function assay 1 hr Inhibition of heat killed Staphylococcus aureus 209P-induced NF-kappaB activation in HEK293 cells expressing TLR2 pretreated for 1 hr before 6 hrs heat killed bacterial stimulation by luciferase reporter gene assay 17938187
HEK293 Function assay 100 uM 1 hr Inhibition of heat killed Escherichia coli K12-induced nuclear translocation of p65 element of NF-kappaB in HEK293 cells expressing TLR2 at 100 uM pretreated for 1 hr before 6 hrs heat killed bacterial stimulation by immunostaining method 17938187
HEK293 Function assay 100 uM 1 hr Inhibition of heat killed Staphylococcus aureus 209P-induced nuclear translocation of p65 element of NF-kappaB in HEK293 cells expressing TLR2 at 100 uM pretreated for 1 hr before 6 hrs heat killed bacterial stimulation by immunostaining method 17938187
RAW264.7 Function assay 1 to 100 uM 6 hrs Inhibition of heat killed Escherichia coli K12-induced TNF alpha production in mouse RAW264.7 cells at 1 to 100 uM after 6 hrs by ELISA 17938187
THP1 Function assay 1 to 100 uM 6 hrs Inhibition of heat killed Escherichia coli K12-induced TNF alpha production in human THP1 cells at 1 to 100 uM after 6 hrs by ELISA 17938187
RAW264.7 Function assay 1 to 100 uM 6 hrs Inhibition of heat killed Staphylococcus aureus 209P-induced TNF alpha production in mouse RAW264.7 cells at 1 to 100 uM after 6 hrs by ELISA 17938187
THP1 Function assay 1 to 100 uM 6 hrs Inhibition of heat killed Staphylococcus aureus 209P-induced TNF alpha production in human THP1 cells at 1 to 100 uM after 6 hrs by ELISA 17938187
THP1 Function assay 100 uM 1 hr Inhibition of FSL1-induced upregulation of MSR1 mRNA expression in in human THP1 cells at 100 uM after 1 hr by RT-PCR 17938187
THP1 Function assay 100 uM 1 hr Inhibition of FSL1-induced upregulation of CD36 mRNA expression in in human THP1 cells at 100 uM after 1 hr by RT-PCR 17938187
THP1 Function assay 100 uM 1 hr Inhibition of FSL1-induced upregulation of DC-SIGN mRNA expression in in human THP1 cells at 100 uM after 1 hr by RT-PCR 17938187
THP1 Function assay 100 uM 1 hr Inhibition of FSL1-induced upregulation of dectin-1 mRNA expression in in human THP1 cells at 100 uM after 1 hr by RT-PCR 17938187
HEK293 Function assay 100 uM Inhibition of DC-SIGN expression in HEK293 cells expressing DC-SIGN at 100 uM by Western blot analysis 17938187
U2OS Function assay 100 uM Activation of SIRT1 in human U2OS cells assessed as decrease in p53 deacetylation level at 100 uM 18046409
293 Function assay 24 hrs Inhibition of TNFalpha induced NF-kappaB activation in human 293 cells after 24 hrs by luciferase reporter gene assay, IC50=16.1μM. 18487053
cortical microglial Function assay 48 hrs Inhibition of LPS-stimulated NO release in rat cortical microglial cells assessed as nitrite accumulation after 48 hrs, IC50=11.5μM. 18588343
HL60 Cytotoxicity assay 48 hrs Cytotoxicity against human HL60 cells after 48 hrs by MTT assay, IC50=36.3μM. 19251420
PBL Function assay 12.5 uM Inhibition of hydrogen peroxide-induced DNA damage in human PBL cells at 12.5 uM by Comet assay 19271734
HL60 Function assay 150 uM 48 hrs Induction of DNA fragmentation in human HL60 cells at 150 uM after 48 hrs by ethidium bromide based gel electrophoresis 19271734
DLKP Antiproliferative assay 5 days Antiproliferative activity against MRP1-expressing human DLKP cells after 5 days by acid phosphatase assay, IC50=10μM. 19481462
DLKP-A Antiproliferative assay 5 days Antiproliferative activity against P-gp expressing human DLKP-A cells after 5 days by acid phosphatase assay, IC50=15μM. 19481462
HT144 Antiproliferative assay 5 days Antiproliferative activity against human HT144 cells after 5 days by acid phosphatase assay, IC50=40μM. 19481462
C2C12 Function assay 50 uM 16 hrs Increase in mitochondrial function in mouse C2C12 cells assessed as enhancement of mitochondrial density at 50 uM after 16 hrs by green FM dye straining-based fluorescence assay 19663498
3T3L1 Antiadipogenic assay 7 days Antiadipogenic activity against mouse 3T3L1 cells assessed as inhibition of differentiation after 7 days by oil-red O staining, IC50=31.4μM. 19757853
SW480 Antiproliferative assay 48 hrs Antiproliferative activity against human SW480 cells assessed as cell viability using propidium iodide staining after 48 hrs, IC50=20μM. 20395019
H460 Antiproliferative assay 72 hrs Antiproliferative activity against human H460 cells after 72 hrs, IC50=12.9μM. 20409723
H460 Cell cycle assay 20 uM 24 hrs Cell cycle arrest in human H460 cells assessed as accumulation at G2/M phase at 20 uM after 24 hrs by propidium iodide staining-based flow cytometry 20409723
HEK293 Function assay 48 hrs Inhibition of TNF-alpha-induced NF-kappaB activity expressed in HEK293 cells after 48 hrs by luciferase reporter gene assay, IC50=0.173μM. 20527891
RAW 264.7 Function assay 20 hrs Inhibition of iNOS-mediated nitric oxide production in LPS-stimulated mouse RAW 264.7 cells pretreated 30 mins before LPS challenge measured after 20 hrs by Griess reaction method relative to control, IC50=15μM. 20527891
Hepa 1c1c7 Function assay Inhibition of quinone reductase 1 in mouse Hepa 1c1c7 cells assessed as drug level required to double enzyme activity by MTT assay, CD=21μM. 20527891
RAW264.7 Function assay 34 uM 15 mins Inhibition of LPS-induced iNOS expression in mouse RAW264.7 cells at 34 uM treated 15 mins before LPS challenge measured after 18 hrs by Western blotting 20527891
Caco-2 Cytotoxicity assay 3 days Cytotoxicity against human Caco-2 cells after 3 days by [3H]thymidine incorporation assay, IC50=24.35μM. 20627379
HT-29 Cytotoxicity assay 3 days Cytotoxicity against human HT-29 cells after 3 days by [3H]thymidine incorporation assay, IC50=45.3μM. 20627379
MDA-MB-231 Antitumor assay 6 days Antitumor activity against human MDA-MB-231 cells after 6 days by SRB assay, IC50=20.5μM. 20728369
CCD-18Co Antiinflammatory assay 1 uM 18 hrs Antiinflammatory activity in human CCD-18Co cells assessed inhibition of IL1beta-induced PGE2 production at 1 uM after 18 hrs 20866032
CCD-18Co Antiinflammatory assay 2.5 to 25 uM 18 hrs Antiinflammatory activity in human CCD-18Co cells assessed as inhibition of IL1beta-induced PGE2 production at 2.5 to 25 uM after 18 hrs 20866032
Caco2 Function assay 6 hrs Metabolic stability in human Caco2 cells after 6 hrs by LC-MS-MS analysis 20866032
HT22 Neuroprotective assay 24 hrs Neuroprotective activity in mouse HT22 cells assessed as protection against glutamate-induced oxytosis after 24 hrs by MTT assay, EC50=4.667μM. 21129978
SW480 Cytotoxicity assay 10 uM 2 days Cytotoxicity against human SW480 cells at 10 uM for 2 days by vi-cell cell viability analysis 21291235
HCT116 Cytotoxicity assay 10 uM 2 days Cytotoxicity against human HCT116 cells at 10 uM for 2 days by vi-cell cell viability analysis 21291235
HCT116 Cytotoxicity assay 10 uM 4 days Cytotoxicity against human HCT116 cells at 10 uM for 4 days by vi-cell cell viability analysis 21291235
LS 174T Cytotoxicity assay 10 uM 4 days Cytotoxicity against human LS 174T cells at 10 uM for 4 days by vi-cell cell viability analysis 21291235
LS 174T Cytotoxicity assay 10 uM 2 days Cytotoxicity against human LS 174T cells at 10 uM for 2 days by vi-cell cell viability analysis 21291235
LS174T Function assay 100 uM 36 hrs Inhibition of Wnt/beta-casein in human LS174T cells assessed as reduction in Ki67 mRNA level at 100 uM after 36 hrs by RT-PCR analysis 21291235
LS174T Function assay 100 uM 36 hrs Inhibition of Wnt/beta-casein in human LS174T cells assessed as reduction in c-Myc mRNA level at 100 uM after 36 hrs by RT-PCR analysis 21291235
LS174T Function assay 100 uM 36 hrs Inhibition of Wnt/beta-casein in human LS174T cells assessed as reduction in CD44 mRNA level at 100 uM after 36 hrs by RT-PCR analysis 21291235
LS174T Function assay 100 uM 36 hrs Inhibition of Wnt/beta-casein in human LS174T cells assessed as reduction in Lgr5 mRNA level at 100 uM after 36 hrs by RT-PCR analysis 21291235
LS174T Function assay 100 uM 36 hrs Inhibition of Wnt/beta-casein in human LS174T cells assessed as reduction in survivin mRNA level at 100 uM after 36 hrs by RT-PCR analysis 21291235
LS174T Function assay 100 uM Inhibition of Wnt/beta-casein in human LS174T cells assessed as increase in p21WAF1/CIP1 protein level at 100 uM by Western blotting 21291235
LS174T Function assay 100 uM Inhibition of Wnt/beta-casein in human LS174T cells assessed as reduction in cyclin B1 protein level at 100 uM by Western blotting 21291235
LS174T Function assay 100 uM Inhibition of Wnt/beta-casein in human LS174T cells assessed as reduction in c-Myc protein level at 100 uM by Western blotting 21291235
LS174T Function assay 100 uM Inhibition of Wnt/beta-casein in human LS174T cells assessed as reduction in Cyclin D1 protein level at 100 uM by Western blotting 21291235
HEK293T Function assay 100 uM 12 hrs Inhibition of LiCl-induced Wnt/beta-casein in human HEK293T cells transfected with TOP Flash assessed as decrease in luciferase expression at 100 uM after 12 hrs by dual luciferase reporter assay 21291235
SW480 Cytotoxicity assay 10 uM 4 days Cytotoxicity against human SW480 cells at 10 uM for 4 days by vi-cell cell viability analysis 21291235
LS 174T Function assay 100 uM Inhibition of Wnt/beta-casein in human LS 174T cells assessed as reduction in TCF4 protein level at 100 uM by Western blotting 21291235
LS 174T Function assay 100 uM Inhibition of Wnt/beta-casein in human LS 174T cells assessed as reduction in pygopus2 protein level at 100 uM by Western blotting 21291235
HEK293T Function assay 100 uM 12 hrs Inhibition of Wnt/beta-casein in human HEK293T cells transfected with TOP Flash assessed as decrease in luciferase expression at 100 uM after 12 hrs by dual luciferase reporter assay 21291235
32Dcl3 Function assay 10 uM 1 hr Radioprotective activity against 0 to 7 Gy gamma radiation-induced death in mouse 32Dcl3 cells at 10 uM treated 1 hr prior to irradiation after 7 days by microscopy 21826253
HeLa Antiproliferative assay 48 hrs Antiproliferative activity against human HeLa cells assessed as cell viability after 48 hrs by SRB assay, IC50=0.0000225μM. 21851083
SK-N-SH Antiproliferative assay 48 hrs Antiproliferative activity against human SK-N-SH cells assessed as cell viability after 48 hrs by SRB assay, IC50=0.0000403μM. 21851083
A549 Antiproliferative assay 48 hrs Antiproliferative activity against human A549 cells assessed as cell viability after 48 hrs by SRB assay, IC50=0.0000447μM. 21851083
MCF7 Antiproliferative assay 48 hrs Antiproliferative activity against human MCF7 cells assessed as cell viability after 48 hrs by SRB assay, IC50=0.0000791μM. 21851083
RAW264.7 Antiinflammatory assay 50 uM 1.5 hrs Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha production at 50 uM after 1.5 hrs by ELISA 22088309
HEK293 Function assay Inhibition of TNFalpha-activated NF-kappaB expressed in HEK293 cells by luciferase reporter gene assay, IC50=0.98μM. 22115839
Hepa-1c1c7 Function assay Induction of QR1 activity in mouse Hepa-1c1c7 cells using MTT as substrate by spectrophotometry, CD=21μM. 22115839
RAW264.7 Antiinflammatory assay 30 mins Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 30 mins before LPS challenge measured after 24 hrs by Griess method, IC50=30.71μM. 22115839
B16F10 Antimelanogenic assay 200 uM 72 hrs Antimelanogenic activity in mouse assessed as cellular melanin content B16F10 cells at 200 uM after 72 hrs spectrophotometric analysis 22189272
HEK293 Function assay Inhibition of TNF-alpha activated NF-kappaB expressed in HEK293 cells by luciferase reporter gene assay, IC50=0.98μM. 22386564
Hepa-1c1c7 Function assay Induction of QR1 in mouse Hepa-1c1c7 cells assessed as concentration required to double QR1 induction by MTT assay, CD=21μM. 22386564
RAW264.7 Function assay 18 hrs Inhibition of iNOS in LPS-stimulated mouse RAW264.7 cells after 18 hrs, IC50=23.2μM. 22386564
RAW264.7 Antiinflammatory assay 30 mins Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 30 mins measured 24 hrs post LPS challenge by Griess method, IC50=30.71μM. 22386564
NIH/3T3 Cytotoxicity assay 96 hrs Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay, IC50=24.22μM. 22749392
HEK293 Function assay Inhibition of TNFalpha-induced NF-kappaB activity expressed in HEK293 cells by luciferase reporter gene assay, IC50=0.98μM. 23142320
Hepa-1c1c7 Function assay 48 hrs Induction of quinone reductase-1 activity in mouse Hepa-1c1c7 cells after 48 hrs by MTT assay, CD=21μM. 23142320
RAW 264.7 Function assay 30 mins Inhibition of LPS-induced iNOS activity in mouse RAW 264.7 cells assessed as inhibition of NO production pretreated with compound for 30 mins before LPS challenge after 24 hrs by Griess reagent method, IC50=23.2μM. 23142320
MCF7 Function assay >100 uM Activation of SIRT1 in human MCF7 cells assessed as reduction in doxorubicin-induced acetyl-p53 level at >100 uM after 6 hrs by Western blotting analysis 23316803
HL60 Cytotoxicity assay 48 hrs Cytotoxicity against human HL60 cells assessed as growth inhibition measured after 48 hrs by XTT assay, IC50=31.8μM. 23547843
HeLa Function assay Inhibition of smad3/4 signaling pathway in human HeLa cells assessed as measured as lowest concentration required 50 to 60 % inhibition of TGF-beta induced luciferase treated 30 mins before induction, MED=33μM. 23547843
HeLa Function assay Inhibition of Hedgehog signaling pathway in human HeLa cells assessed as measured as lowest concentration required 50 to 60 % inhibition of PMA induced luciferase treated 30 mins before induction, MED=40μM. 23547843
HeLa Function assay Inhibition of Hedgehog signaling pathway in human HeLa cells assessed as inhibition of PMA induced luciferase treated 30 mins before induction, IC50=40μM. 23547843
HeLa Function assay Inhibition of Notch signaling pathway in human HeLa cells assessed as measured as lowest concentration required 50 to 60 % inhibition of PMA induced luciferase treated 30 mins before induction, MED=40μM. 23547843
HeLa Function assay Inhibition of Notch signaling pathway in human HeLa cells assessed as inhibition of PMA induced luciferase treated 30 mins before induction, IC50=40μM. 23547843
SK-MEL Cytotoxicity assay 48 hrs Cytotoxicity against human SK-MEL cells assessed as growth inhibition measured after 48 hrs by XTT assay, IC50=47.3μM. 23547843
HL60 Cytotoxicity assay Cytotoxicity against human HL60 cells, ED50=22μM. 23582778
Huh7.5.1 Cytotoxicity assay 72 hrs Cytotoxicity against human Huh7.5.1 cells after 72 hrs, IC50=10.6μM. 23673225
MCF7 Cytotoxicity assay 72 hrs Cytotoxicity against human estrogen receptor positive MCF7 cells after 72 hrs by MTT assay, IC50=28.07μM. 23860590
SKBR3 Cytotoxicity assay 72 hrs Cytotoxicity against human estrogen receptor negative SKBR3 cells after 72 hrs by MTT assay, IC50=41.42μM. 23860590
ScN2a-cl3 Function assay 5 days Inhibition of RML prion protein infected in mouse dividing ScN2a-cl3 cells expressing full length mouse PrP assessed as reduction of PrPsc level after 5 days by Western blotting analysis, EC50=0.58μM. 24183589
ScN2a-cl3 Function assay 5 days Inhibition of RML prion protein infected in mouse dividing ScN2a-cl3 cells expressing full length mouse PrP assessed as reduction of PrPsc level after 5 days by ELISA, EC50=3.06μM. 24183589
SH-SY5Y Neuroprotective assay 10 uM 24 hrs Neuroprotective activity in human SH-SY5Y cells assessed as inhibition H2O2-induced reduction of cell viability at 10 uM after 24 hrs by phase-contrast micrograph analysis 24269515
HEK293 Function assay 6 hrs Inhibition of TNF-alpha-induced NF-kappaB activity in HEK293 cells after 6 hrs by luciferase reporter gene assay, IC50=2.5μM. 24992702
Hepa-1c1c7 Function assay 48 hrs Induction of quinone reductase 1 in mouse Hepa-1c1c7 cells after 48 hrs by MTT assay, CD=21μM. 24992702
HeLa Function assay 10 to 100 uM 24 hrs Induction of SV40 promoter-mediated luciferase gene expression in human HeLa cells at 10 to 100 uM after 24 hrs by RT-PCR analysis 25147604
COLO205 Antiproliferative assay Antiproliferative activity against human COLO205 cells by MTT assay, IC50=23.5μM. 25455486
MGC803 Antiproliferative assay Antiproliferative activity against human MGC803 cells by MTT assay, IC50=42μM. 25455486
MDA468 Antiproliferative assay Antiproliferative activity against human MDA468 cells by MTT assay, IC50=45.2μM. 25455486
HeLa Antiproliferative assay 48 hrs Antiproliferative activity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay, IC50=47.9μM. 25817772
RAW264.7 Anti-inflammatory assay 10 mM 10 mins Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced IL6 production at 10 mM pre-incubated for 10 mins before LPS stimulation for 24 hrs by ELISA method 26048788
RAW264.7 Anti-inflammatory assay 10 mM 10 mins Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNFalpha production at 10 mM pre-incubated for 10 mins before LPS stimulation for 24 hrs by ELISA method 26048788
HaCaT Function assay 1 uM 1 hr Activation of SIRT1 in human HaCaT cells assessed as H4K16 deacetylation at 1 uM after 1 hr by Western blotting method 26689352
HEK293 Function assay Antagonist activity at rat TRPA1 expressed in HEK293 cells assessed as inhibition of AITC-induced increase of intracellular calcium level, IC50=0.75μM. 26750258
HEK293 Function assay Agonist activity at rat TRPA1 expressed in HEK293 cells assessed as induction of intracellular calcium level in absence of AITC, IC50=1.4μM. 26750258
HEK293 Function assay Agonist activity at rat TRPA1 expressed in HEK293 cells assessed as induction of intracellular calcium level in presence of AITC, IC50=2.74μM. 26750258
HEK293 Function assay Antagonist activity at rat TRPA1 expressed in HEK293 cells assessed as inhibition of allyl isothiocyanate-induced increase of intracellular calcium level, IC50=19.9μM. 26750258
U373-MAGI Antiviral assay 50 uM 2 hrs Potentiation of 5-Aza-C-induced antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as 5-Aza-C EC50 at 50 uM preincubated for 2 hrs followed by 5-Aza-C addition for 2 hrs and subsequent viral infection measu, EC50=10μM. 27117260
U373-MAGI Antiviral assay 50 uM 4 hrs Antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as reduction in viral infectivity at 50 uM incubated for 4 hrs prior to viral infection measured at 72 hrs post infection by flow cytometric analysis 27117260
U373-MAGI Function assay 200 uM 6 hrs Reduction in dGTP level in human U373-MAGI cells at 200 uM after 6 hrs by LC-MS/MS analysis 27117260
U373-MAGI Function assay 200 uM 6 hrs Reduction in dTTP level in human U373-MAGI cells at 200 uM after 6 hrs by LC-MS/MS analysis 27117260
U373-MAGI Antiviral assay 25 to 100 uM 2 hrs Potentiation of 5-Aza-C-induced antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as reduction in viral infectivity at 25 to 100 uM preincubated for 2 hrs followed by 5-Aza-C addition for 2 hrs and subsequ 27117260
U373-MAGI Antiviral assay 2 to 8 hrs Antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as reduction in viral infectivity preincubated for 2 to 8 hrs followed by viral infection measured at 72 hrs post infection by flow cytometric analysis 27117260
U373-MAGI Function assay 200 uM 6 hrs Reduction in dCTP level in human U373-MAGI cells at 200 uM after 6 hrs by LC-MS/MS analysis 27117260
U373-MAGI Function assay 50 uM 2 hrs Reduction in dCTP level in human U373-MAGI cells at 50 uM preincubated for 2 hrs followed by 5-aza-C addition measured after 4 hrs by LC-MS/MS analysis 27117260
U373-MAGI Function assay 200 uM 6 hrs Reduction in dATP level in human U373-MAGI cells at 200 uM after 6 hrs by LC-MS/MS analysis 27117260
U373-MAGI Function assay 200 uM 2 hrs Reduction in dRGU-TP level in human U373-MAGI cells at 200 uM preincubated for 2 hrs followed by 5-aza-C addition measured after 4 hrs by LC-MS/MS analysis 27117260
U373-MAGI Function assay 50 uM 2 hrs Increase in 5-aza-dCTP/dCTP ratio in human U373-MAGI cells at 50 uM preincubated for 2 hrs followed by 5-aza-dC addition measured after 4 hrs by LC-MS/MS analysis relative to 5-aza-dC 27117260
U373-MAGI Function assay 200 uM 2 hrs Reduction in dCTP level in human U373-MAGI cells at 200 uM preincubated for 2 hrs followed by 5-aza-C addition measured after 4 hrs by LC-MS/MS analysis relative to 5-aza-C 27117260
U373-MAGI Antiviral assay 50 uM 2 to 72 hrs Potentiation of 5-Aza-C-induced antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as reduction in U5-gag level at 50 uM after 2 to 72 hrs by qPCR method 27117260
U373-MAGI Antiviral assay 50 uM 6 hrs Antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as reduction in gag level at 50 uM measured at 6 hrs post infection by qPCR method 27117260
U373-MAGI Function assay 200 uM 2 hrs Increase in 5-aza-dCTP/dCTP ratio in human U373-MAGI cells at 200 uM preincubated for 2 hrs followed by 5-aza-dC addition measured after 4 hrs by LC-MS/MS analysis relative to 5-aza-dC 27117260
U373-MAGI Function assay 200 uM 2 hrs Reduction in 5-aza-dCTP level in human U373-MAGI cells at 200 uM preincubated for 2 hrs followed by 5-aza-C addition measured after 4 hrs by LC-MS/MS analysis 27117260
U373-MAGI Antiviral assay 50 uM 2 to 8 hrs Potentiation of 5-Aza-C-induced antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as reduction in viral infectivity at 50 uM preincubated for 2 to 8 hrs followed by 5-Aza-C addition for 2 hrs and subsequen 27117260
U373-MAGI Antiviral assay 25 uM 2 hrs Potentiation of 5-Aza-dC-induced antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as reduction in viral infectivity at 25 uM preincubated for 2 hrs followed by 5-Aza-dC addition for 2 hrs and subsequent v 27117260
U373-MAGI Function assay 50 uM 2 hrs Increase in 5-aza-dCTP/dCTP ratio in human U373-MAGI cells at 50 uM preincubated for 2 hrs followed by 5-aza-C addition measured after 4 hrs by LC-MS/MS analysis relative to 5-aza-C 27117260
U373-MAGI Function assay 50 uM 2 hrs Reduction in dCTP level in human U373-MAGI cells at 50 uM preincubated for 2 hrs followed by 5-aza-dC addition measured after 4 hrs by LC-MS/MS analysis relative to 5-aza-dC 27117260
U373-MAGI Function assay 200 uM 2 hrs Reduction in dCTP level in human U373-MAGI cells at 200 uM preincubated for 2 hrs followed by 5-aza-dC addition measured after 4 hrs by LC-MS/MS analysis relative to 5-aza-dC 27117260
U373-MAGI Antiviral assay 50 uM 2 to 72 hrs Potentiation of 5-Aza-dC-induced antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as reduction in U5-gag level at 50 uM after 2 to 72 hrs by qPCR method 27117260
U373-MAGI Antiviral assay 50 uM 2 to 72 hrs Potentiation of 5-Aza-C-induced antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as reduction in gag level at 50 uM after 2 to 72 hrs by qPCR method 27117260
U373-MAGI Antiviral assay 50 uM 2 to 72 hrs Potentiation of 5-Aza-dC-induced antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as reduction in gag level at 50 uM after 2 to 72 hrs by qPCR method 27117260
U373-MAGI Antiviral assay 50 uM 6 hrs Antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as reduction in U5-gag level at 50 uM measured at 6 hrs post infection by qPCR method 27117260
DH5aplha Function assay 2 mins Inhibition of recombinant human CYP1A1 expressed in Escherichia coli DH5aplha cells assessed as O-deethylation of ethoxyresorufin in presence of NADPH measured after 2 mins by spectrofluorometric method, IC50=34μM. 27265259
MDAH 2774 Cytotoxicity assay 72 hrs Cytotoxicity against human MDAH 2774 cells after 72 hrs by MTT assay, CD50=14.6μM. 27515319
T24 Cytotoxicity assay 72 hrs Cytotoxicity against human T24 cells after 72 hrs by MTT assay, CD50=22.7μM. 27515319
MDAH 2774 Cytotoxicity assay 48 hrs Cytotoxicity against human MDAH 2774 cells after 48 hrs by MTT assay, CD50=23μM. 27515319
DU145 Cytotoxicity assay 72 hrs Cytotoxicity against human DU145 cells after 72 hrs by MTT assay, CD50=27.9μM. 27515319
MHRF Cytotoxicity assay 72 hrs Cytotoxicity against human MHRF cells after 72 hrs by MTT assay, CD50=32μM. 27515319
MDAH 2774 Cytotoxicity assay 24 hrs Cytotoxicity against human MDAH 2774 cells after 24 hrs by MTT assay, CD50=36.9μM. 27515319
HCT116 Cytotoxicity assay 100 uM 48 hrs Cytotoxicity against human HCT116 cells assessed as cell growth inhibition at 100 uM after 48 hrs by MTT assay 27887843
Bel7402 Cytotoxicity assay 100 uM 48 hrs Cytotoxicity against human Bel7402 cells assessed as cell growth inhibition at 100 uM after 48 hrs by MTT assay 27887843
HepG2 Function assay 5 hrs Activation of Nrf2 (unknown origin) expressed in human HepG2 cells after 5 hrs by ARE-driven luciferase reporter gene assay, EC50=5.4μM. 28126440
HEK293 Growth inhibition assay 2 days Growth inhibition of HEK293 cells after 2 days by MTT assay, IC50=17μM. 28408224
MCF7 Growth inhibition assay 2 days Growth inhibition of human MCF7 cells after 2 days by MTT assay, IC50=34μM. 28408224
Ramos Growth inhibition assay 2 days Growth inhibition of human Ramos cells after 2 days by MTT assay, IC50=37μM. 28408224
ALL5 Cytotoxicity assay 120 hrs Cytotoxicity against human ALL5 cells after 120 hrs by MTT method, IC50=10.5μM. 28499732
HEK293 Function assay Inhibition of human TRPA1 expressed in HEK293 cells assessed as decrease in AITC-induced current response by whole cell patch clamp method, IC50=0.75μM. 28576617
LN229 Cytotoxicity assay 48 hrs Cytotoxicity against human LN229 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50=11μM. 28654265
NCI-H460 Cytotoxicity assay 48 hrs Cytotoxicity against human NCI-H460 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50=12μM. 28654265
MML1 Cytotoxicity assay 48 hrs Cytotoxicity against human MML1 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50=12μM. 28654265
BxPC3 Cytotoxicity assay 48 hrs Cytotoxicity against human BxPC3 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50=14μM. 28654265
SK-MEL-2 Cytotoxicity assay 48 hrs Cytotoxicity against human SK-MEL-2 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50=14μM. 28654265
MDA-MB-231 Cytotoxicity assay 48 hrs Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50=15μM. 28654265
A549 Cytotoxicity assay 48 hrs Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50=16μM. 28654265
U87 Cytotoxicity assay 48 hrs Cytotoxicity against human U87 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50=20μM. 28654265
T47D Cytotoxicity assay 48 hrs Cytotoxicity against human T47D cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50=25μM. 28654265
HT-29 Cytotoxicity assay 48 hrs Cytotoxicity against human HT-29 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50=27μM. 28654265
COLO201 Cytotoxicity assay 48 hrs Cytotoxicity against human COLO201 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50=37μM. 28654265
PANC1 Cytotoxicity assay 48 hrs Cytotoxicity against human PANC1 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50=39μM. 28654265
A549 Growth inhibition assay Growth inhibition of human A549 cells, IC50=30μM. 28814374
BV2 Antineuroinflammatory assay 24 hrs Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction based assay, IC50=18.66μM. 28911817
A375 Function assay 25 uM 24 hrs Inhibition of alpha-MSH-induced TRP-1 expression in human A375 cells at 25 uM after 24 hrs by Western blot method 29150333
A375 Function assay 25 uM 24 hrs Inhibition of alpha-MSH-induced TRP-2 expression in human A375 cells at 25 uM after 24 hrs by Western blot method 29150333
A375 Function assay 25 uM 4 hrs Inhibition of alpha-MSH-induced reactive oxygen species generation in human A375 cells at 25 uM after 4 hrs by DCFDA staining-based fluorescence assay 29150333
HEK293T Cytotoxicity assay 24 hrs Cytotoxicity against HEK293T cells after 24 hrs by MTT assay, CC50=22.75μM. 29172079
3T3L1 Function assay 1 to 10 uM 6 days Inhibition of triglyceride accumulation in mouse 3T3L1 cells at 1 to 10 uM after 6 days by ORO staining-based microscopic method 29172079
RAW264.7 Function assay 10 uM 24 hrs Inhibition of LPS-induced TNF-alpha production in rat RAW264.7 cells at 10 uM after 24 hrs by ELISA 29407944
RAW264.7 Function assay 10 uM 24 hrs Inhibition of LPS-induced IL-6 production in rat RAW264.7 cells at 10 uM after 24 hrs by ELISA 29407944
SK-N-MC qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells 29435139
BT-37 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells 29435139
BV2 Antineuroinflammatory assay 24 hrs Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced IL-1beta production after 24 hrs by ELISA, IC50=8.7μM. 29499485
BV2 Antineuroinflammatory assay 24 hrs Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced TNFalpha production after 24 hrs by ELISA, IC50=9.5μM. 29499485
BV2 Antineuroinflammatory assay 30 mins Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production pretreated for 30 mins followed by LPS stimulation and measured after 24 hrs by Griess assay, IC50=11.1μM. 29499485
J774 Antiinflammatory assay 24 hrs Antiinflammatory activity in mouse J774 cells assessed as reduction in LPS-induced IL6 expression after 24 hrs by ELISA, IC50=6.8μM. 29726680
J774 Antiinflammatory assay 24 hrs Antiinflammatory activity in mouse J774 cells assessed as reduction in LPS-induced nitric oxide production after 24 hrs by Griess assay, IC50=12.15μM. 29726680
J774 Antiinflammatory assay 24 hrs Antiinflammatory activity in mouse J774 cells assessed as reduction in LPS-induced MCP1 expression after 24 hrs by ELISA, IC50=13.6μM. 29726680
RAW 264.7 Function assay 24 hrs Inhibition of NFkappaB in mouse RAW 264.7 cells assessed as reduction in LPS induced NO production after 24 hrs in presence of OBHS by Griess assay, IC50=11μM. 30053783
RAW 264.7 Function assay 24 hrs Inhibition of NFkappaB in mouse RAW 264.7 cells assessed as reduction in LPS induced NO production after 24 hrs by Griess assay, IC50=13.1μM. 30053783
MCF7 Antiproliferative assay 72 hrs Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay, IC50=22.9μM. 30053783
MCF7 Antiproliferative assay 72 hrs Antiproliferative activity against human MCF7 cells after 72 hrs in presence of OBHS by MTT assay, IC50=25.4μM. 30053783
BV2 Antineuroinflammatory assay 10 to 30 uM 24 hrs Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production at 10 to 30 uM after 24 hrs by Griess assay 30096650
RAW264.7 Antiinflammatory assay 1 hr Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS/IFNgamma-induced NO production by measuring NO levels incubated with LPS/IFNgamma for 1 hr followed by compound addition measured after 48 hrs by Griess assay (Rvb = 55 +/- 2., Activity=44.5μM. 30193941
T cells Antiproliferative assay 50 uM 1 hr Antiproliferative activity against Con-A-induced T cells isolated from splenocytes of C57/BL6 mouse at 50 uM incubated with Con-A for 1 hr followed by compound addition measured after 72 hrs by MTT assay 30193941
B cells Antiproliferative assay 50 uM 1 hr Antiproliferative activity against LPS-induced B cells isolated from splenocytes of C57/BL6 mouse at 50 uM incubated with LPS for 1 hr followed by compound addition measured after 72 hrs by MTT assay 30193941
RAW264.7 Immunomodulatory assay 50 uM 1 hr Immunomodulatory activity in LPS-stimulated mouse RAW264.7 cells assessed as decrease in CD80 expression at 50 uM incubated with LPS for 1 hr followed by compound addition measured after 24 hrs by flow cytometry 30193941
RAW264.7 Immunomodulatory assay 50 uM 1 hr Immunomodulatory activity in LPS-stimulated mouse RAW264.7 cells assessed as decrease in CD86 expression at 50 uM incubated with LPS for 1 hr followed by compound addition measured after 24 hrs by flow cytometry 30193941
HBZY-1 Function assay 6 uM Activation of Nrf2 in rat HBZY-1 cells assessed as increase in NQO-1 level at 6 uM by Western blot analysis 30408749
HBZY-1 Function assay 6 uM Activation of Nrf2 in rat HBZY-1 cells assessed as increase in HO-1 level at 6 uM by Western blot analysis 30408749
HBZY-1 Function assay 6 uM Activation of Nrf2 in rat HBZY-1 cells assessed as increase in GCLM level at 6 uM by Western blot analysis 30408749
HBZY-1 Function assay 6 uM Activation of Nrf2 in rat HBZY-1 cells assessed as increase in GCLC level at 6 uM by Western blot analysis 30408749
HBZY-1 Function assay 6 uM 24 hrs Activation of Nrf2 in rat HBZY-1 cells assessed as increase in NQO-1 mRNA expression at 6 uM after 24 hrs by RT-PCR analysis 30408749
HBZY-1 Function assay 6 uM 24 hrs Activation of Nrf2 in rat HBZY-1 cells assessed as increase in HO-1 mRNA expression at 6 uM after 24 hrs by RT-PCR analysis 30408749
HBZY-1 Function assay 6 uM 24 hrs Activation of Nrf2 in rat HBZY-1 cells assessed as increase in GCLM mRNA expression at 6 uM after 24 hrs by RT-PCR analysis 30408749
HBZY-1 Function assay 6 uM 24 hrs Activation of Nrf2 in rat HBZY-1 cells assessed as increase in GCLC mRNA expression at 6 uM after 24 hrs by RT-PCR analysis 30408749
BV2 Antineuroinflammatory assay 30 mins 24 hrs Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production pretreated for 30 mins followed by LPS-stimulation for 24 hrs by Griess assay, IC50=11.1μM. 30771601
MCF7 Antioxidant assay 100 uM 24 hrs Antioxidant activity in human MCF7 cells assessed as decrease in reactive oxygen species generation at 100 uM incubated for 24 hrs by CellROX green/Hoechst 33342 staining based assay 30921758
RAW264.7 Antiinflammatory assay 10 uM 1 hr Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production at 10 uM pretreated for 1 hr followed by LPS stimulation and measured after 24 hrs by Griess reagent based assay 31077997
HBZY-1 Function assay Binding affinity to Keap1 in rat HBZY-1 cells assessed as induction of Nrf2 nuclear translocation by measuring increase in ratio of nuclear to cytosolic Nrf2 level by Western blot analysis 31301564
HBZY-1 Function assay Binding affinity to Keap1 in rat HBZY-1 cells assessed as induction of Keap1/Nrf2 signaling by measuring increase in NQO-1 protein expression by Western blot analysis 31301564
HBZY-1 Function assay Binding affinity to Keap1 in rat HBZY-1 cells assessed as induction of Keap1/Nrf2 signaling by measuring increase in HO-1 protein expression by Western blot analysis 31301564
HBZY-1 Function assay Binding affinity to Keap1 in rat HBZY-1 cells assessed as induction of Keap1/Nrf2 signaling by measuring increase in GCLM protein expression by Western blot analysis 31301564
HBZY-1 Function assay Binding affinity to Keap1 in rat HBZY-1 cells assessed as induction of Keap1/Nrf2 signaling by measuring increase in GCLC protein expression by Western blot analysis 31301564
HBZY-1 Function assay 6 uM Binding affinity to Keap1 in rat HBZY-1 cells assessed as induction of Keap1/Nrf2 signaling by measuring increase in NQO-1 mRNA expression at 6 uM by RT-PCR analysis 31301564
HBZY-1 Function assay 6 uM Binding affinity to Keap1 in rat HBZY-1 cells assessed as induction of Keap1/Nrf2 signaling by measuring increase in HO-1 mRNA expression at 6 uM by RT-PCR analysis 31301564
HBZY-1 Function assay 6 uM Binding affinity to Keap1 in rat HBZY-1 cells assessed as induction of Keap1/Nrf2 signaling by measuring increase in GCLM mRNA expression at 6 uM by RT-PCR analysis 31301564
HBZY-1 Function assay 6 uM Binding affinity to Keap1 in rat HBZY-1 cells assessed as induction of Keap1/Nrf2 signaling by measuring increase in GCLC mRNA expression at 6 uM by RT-PCR analysis 31301564
RAW264.7 Antiinflammatory assay 2 hrs Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS/IFNgamma-induced NO production by measuring NO level preincubated for 2 hrs and followed by LPS/IFNgamma addition and measured after 24 hrs by Griess assay, IC50=44.1μM. 31350127
PMNL Function assay 15 mins Inhibition of 5-LOX in human PMNL cells assessed as A23187-stimulated LTB4 production preincubated for 15 mins followed by A23187 addition and measured after 10 mins by HPLC analysis, IC50=4.9μM. 31351395
H9c2 Antioxidant assay 80 nM to 2 uM 18 hrs Antioxidant activity in rat H9c2 cells assessed as reduction in hypoxia-induced NO release at 80 nM to 2 uM preincubated for 18 hrs followed by incubated in hypoxia for 48 hrs by griess assay 31351395
H9c2 Antioxidant assay 2 uM 18 hrs Antioxidant activity in rat H9c2 cells assessed as increase in hypoxia-induced reduction of MnSOD expression at 2 uM preincubated for 18 hrs followed by incubated in hypoxia for 48 hrs by Western blot analysis 31351395
TOV112D Cytotoxicity assay 96 hrs Cytotoxicity against human TOV112D cells transfected with empty vector assessed as reduction in cell viability incubated for 96 hrs by MTT assay, IC50=10.67μM. 31514018
TOV112D Cytotoxicity assay 96 hrs Cytotoxicity against human TOV112D cells expressing NQO2 assessed as reduction in cell viability incubated for 96 hrs by MTT assay, IC50=11μM. 31514018
SKOV3 Cytotoxicity assay 96 hrs Cytotoxicity against human SKOV3 cells transfected with non-targeted vector assessed as reduction in cell viability incubated for 96 hrs in presence of doxycycline by MTT assay, IC50=29μM. 31514018
SKOV3 Cytotoxicity assay 96 hrs Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay, IC50=36.3μM. 31514018
SKOV3 Cytotoxicity assay 96 hrs Cytotoxicity against human SKOV3 cells transfected with shRNA assessed as reduction in cell viability incubated for 96 hrs in presence of doxycycline by MTT assay, IC50=39.67μM. 31514018
HuH7 Apoptosis assay 100 uM 48 hrs Induction of apoptosis in human HuH7 cells transfected with ShSGK1 assessed as late apoptosis at 100 uM incubated for 48 hrs by annexin V and 7-AAD staining based assay 31539779
HUH7 Function assay 100 uM 6 hrs Inhibition of insulin-induced SGK1 in human HUH7 cells at 100 uM using peptide as substrate incubated for 6 hrs by scintillation counter method 31539779
HuH7 Function assay 100 uM 6 hrs Inhibition of SGK1 in human HuH7 cells assessed as reduction in insulin-induced MDM2 phosphorylation on Ser166 at 100 uM incubated for 6 hrs by Western blot analysis 31539779
HuH7 Antiproliferative assay 100 uM 48 hrs Antiproliferative activity against human HuH7 cells assessed as reduction in cell viability at 100 uM incubated for 48 hrs by trypan blue dye based assay 31539779
HuH7 Apoptosis assay 100 uM 48 hrs Induction of apoptosis in human HuH7 cells assessed as increase in early apoptotic cells at 100 uM incubated for 48 hrs by annexin V and 7-AAD staining based assay 31539779
HuH7 Apoptosis assay 100 uM 48 hrs Induction of apoptosis in human HuH7 cells assessed as increase in late apoptotic cells at 100 uM incubated for 48 hrs by annexin V and 7-AAD staining based assay 31539779
HuH7 Apoptosis assay 100 uM 48 hrs Induction of apoptosis in human HuH7 cells assessed as increase in necrotic cells at 100 uM incubated for 48 hrs by annexin V and 7-AAD staining based assay 31539779
HuH7 Antiproliferative assay 100 uM 48 hrs Antiproliferative activity against human HuH7 cells transfected with ShSGK1 assessed as reduction in cell viability at 100 uM incubated for 48 hrs by trypan blue dye based assay 31539779
HuH7 Antiproliferative assay 100 uM 48 hrs Antiproliferative activity against human HuH7 cells overexpressing EGFP assessed as reduction in cell viability at 100 uM incubated for 48 hrs by trypan blue dye based assay 31539779
HuH7 Apoptosis assay 100 uM 48 hrs Induction of apoptosis in human HuH7 cells transfected with ShSGK1 assessed as early apoptosis at 100 uM incubated for 48 hrs by annexin V and 7-AAD staining based assay 31539779
HuH7 Apoptosis assay 100 uM 48 hrs Induction of apoptosis in human HuH7 cells overexpressing EGFP at 100 uM incubated for 48 hrs by annexin V and 7-AAD staining based assay 31539779
Click to View More Cell Line Experimental Data

Biological Activity

Description Resveratrol has a wide spectrum of targets including cyclooxygenases(i.e. COX, IC50=1.1 μM), lipooxygenases（LOX, IC50=2.7 μM）, kinases, sirtuins and other proteins. It has anti-cancer, anti-inflammatory, blood-sugar-lowering and other beneficial cardiovascular effects. Resveratrol induces mitophagy/autophagy and autophagy-dependent apoptosis.
Targets
SIRT1 [2]
(Cell-free assay)		 SIRT2 [2]
(Cell-free assay)		 Quinone reductase 2 [9]
(Cell-free assay)		 IKK β [1]
(Cell-free assay)		 COX1 [9]
(Cell-free assay)		 Click to View More Targets
88 nM 1 μM 1.1 μM
In vitro
In vitro Resveratrol inhibits the activity of Cyclooxygenase and lipooxygenase, PKCs and p56lck, ERK1, JNK1, p38, IKK β, Src, STAT3, Ribonucleotide Reductase, DNA polymerases α and δ, PKD, PKC α, Quinone reductase 2, and Aromatase with IC50 of from 0.035-60 μM. Resveratrol is also an activator of Adenylyl cyclase and AMPK with EC50 of 0.8 μM and 50 μM, respectively. The roles of Resveratrol as inhibitor or activator enable its effects on decreasing cell inflammatory associated behaviors, growth inhibition and induction of apoptosis in cancer cells, reversal of endothelin-1 stimulated cell responses, inhibition of phorbol ester-induced expression of COX-2, inhibition of DNA synthesis in cell, resistance to menadione-induced cell death, and improvement of cell mitochondrial function and glucose/lipid metabolism. [1] Resveratrol is also an activator of sirtuins. Resveratrol lowers the Michaelis constant of SIRT1 for both the acetylated substrate and NAD+, and increases cell survival by stimulating SIRT1-dependent deacetylation of p53. In yeast, Resveratrol mimics calorie restriction by stimulating Sir2, increasing DNA stability and extending lifespan. [2] Resveratrol is effective at protecting isolated rat hearts against ischemia/reperfusion injury via its antioxidant activity, with improved recovery of developed pressure and aortic flow, reduction of malondialdehyde concentrations and reduction of infarct size. [3]
Cell Research Cell lines Human breast cancer cell MCF-7
Concentrations 30-300 μM
Incubation Time 2 days
Method

Cells are plated in flat-bottomed, 96-well microtiter plates (4000 cells/6.4-mm-diameter well). After 12–24 hr, cells are treated with DMSO (0.1–0.3%) or increasing doses of Resveratrol. After 48 h of treatment, cells are treated with 10μL of MTT reagent for 4 hr at 37 ℃ and then treated with 100 μL of solubilization solution at 37 ℃ overnight. The quantity of formazan product is measured using a spectrophotometric microtiter plate reader at 570 nm wavelength.
Experimental Result Images Methods Biomarkers Images PMID
Western blot Nanog / Oct-4 / Sox-2 p-EGFR / EGFR / p-HER2 / HER2 / p-ERK / ERK / PTEN 21304978
Growth inhibition assay Cell viability 23272133
In Vivo
In vivo Resveratrol improves health and survival of mice on a high-calorie diet. Resveratrol (22.4 mg/kg/day) shifts the physiology of middle-aged mice on a high-calorie diet towards that of mice on a standard diet and significantly increases their survival. Resveratrol produces changes associated with longer lifespan, including increased insulin sensitivity, reduced insulin-like growth factor-1 (IGF-I) levels, increased AMP-activated protein kinase (AMPK) and peroxisome proliferator-activated receptor-γcoactivator 1α(PGC-1α) activity, increased mitochondrial number, and improved motor function. Resveratrol opposed the effects of the high-calorie diet in 144 out of 153 significantly altered pathways. [3] Resveratrol has been shown to inhibit the initiation and growth of tumors in a wide variety of rodent cancer models. Dose of Resveratrol as low as 200 μg/kg daily already shows efficacy in a rat model of colon carcinogenesis. At higher dose of 40 mg/kg, Resveratrol increases the survival of mice with subcutaneous neuroblastomas from 0% to 70%. Resveratrol inhibits vascularization in the corneal micropocket assay in mice at a dose of only 48 μg/kg when administered daily. [3] Resveratrol shows beneficial effects on heart disease. Resveratrol blocks the increase in platelet aggregation induced by a hypercholesterolaemic diet. Resveratrol increase expression of both endothelial and inducible nitric oxide synthase. In stroke-prone, spontaneously hypertensive rats, resveratrol significantly reduces markers of oxidative stress such as glycated albumin in serum, and 8-hydroxyguanos-ine in urine. Providing Resveratrol in drinking water for 15 days (1 mg/kg) is sufficient to improve the recovery in function and coronary flow of isolated hearts. [3] Resveratrol displays anti-inflammatory activity in vivo. Resveratrol significantly reduces both acute and chronic chemically induced oedema, lipopolysaccharide-induced airway inflammation and osteoarthritis, and helps to prevent allograft rejection. Intravenously administered Resveratrol decreases inflammation induced by ischaemia/reperfusion, oxidants generated by hypoxanthine/xanthine oxidase (HX/XO) or platelet-activating factor, but not leukotriene B4 in rats. [3] Resveratrol shows beneficial effects on stroke and brain damage. Resveratrol administered intravenously significantly decreased ischaemic volume and brain water content at the extremely low doses of 100 ng/kg and 1 μg/kg after middle cerebral artery occlusion in rats. [5]
Animal Research Animal Models Human ovarian xenografts PA-1
Dosages 100 mg/kg
Administration i.p. daily for consecutive 4 weeks
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05684848 Recruiting
Wheezing|Recurrent Respiratory Tract Infections
Noos S.r.l.
 November 1 2022 Not Applicable
NCT03743636 Completed
Peripheral Artery Disease
Northwestern University|American Heart Association
 October 1 2018 Phase 3

Chemical Information & Solubility

Molecular Weight 228.24 Formula

C14H12O3
CAS No. 501-36-0 SDF Download Resveratrol SDF
Smiles C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O
Storage (From the date of receipt)

In vitro
Batch:

DMSO : 46 mg/mL ( (201.54 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : Insoluble

Ethanol : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Resveratrol | Resveratrol ic50 | Resveratrol price | Resveratrol cost | Resveratrol solubility dmso | Resveratrol purchase | Resveratrol manufacturer | Resveratrol research buy | Resveratrol order | Resveratrol mouse | Resveratrol chemical structure | Resveratrol mw | Resveratrol molecular weight | Resveratrol datasheet | Resveratrol supplier | Resveratrol in vitro | Resveratrol cell line | Resveratrol concentration | Resveratrol nmr